Tumor-Associated Trypsin Inhibitor (Tati) in Benign and Malignant Gastric Disease
| Autor: | J F Legorburu Escudero, A Loizate Toricaguena, A. Lamiquiz Vallejo, M.J. Dominguez Merru-Urrutia |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
Pathology medicine.medical_specialty Trypsin inhibitor Microgram Clinical Biochemistry Stomach Diseases Disease Sensitivity and Specificity Gastroenterology Antigen Stomach Neoplasms Internal medicine Biomarkers Tumor medicine Humans Antigens Tumor-Associated Carbohydrate In patient Stage (cooking) Tumor-Associated Trypsin Inhibitor Aged Chemistry Cancer General Medicine Middle Aged medicine.disease digestive system diseases Carcinoembryonic Antigen Trypsin Inhibitor Kazal Pancreatic Tissue Plasminogen Activator Female |
| Zdroj: | Scandinavian Journal of Clinical and Laboratory Investigation. 51:59-62 |
| ISSN: | 1502-7686 0036-5513 |
| DOI: | 10.3109/00365519109104629 |
| Popis: | We have evaluated the clinical utility of tumor-associated trypsin inhibitor (TATI) as a marker for gastric cancer. For comparison we also studied CEA, CA19-9, CA-50 and TPA. The study comprised 93 patients with cancer and 45 with gastroduodenal ulcers. In 95% of the patients with benign disease the serum TATI concentrations were below 30 micrograms/l. Using this concentration as cut-off level 46% of the cancer patients had elevated levels. These were most common in advanced disease (68% in stage IVB) and patients with anaplastic tumors. Therefore TATI was a useful complement to CEA, which was most often elevated in patients with differentiated tumors. Addition of TATI to the battery of other markers increased the overall sensitivity for cancer from 69% to 80%. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|